Genetic Mechanisms of Immune Evasion in Colorectal Cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 100 of the 103 references it cites were found in a registry or an index.
Abstract
To understand the genetic drivers of immune recognition and evasion in colorectal cancer, we analyzed 1,211 colorectal cancer primary tumor samples, including 179 classified as microsatellite instability–high (MSI-high). This set includes The Cancer Genome Atlas colorectal cancer cohort of 592 samples, completed and analyzed here. MSI-high, a hypermutated, immunogenic subtype of colorectal cancer, had a high rate of significantly mutated genes in important immune-modulating pathways and in the antigen presentation machinery, including biallelic losses of B2M and HLA genes due to copy-number alterations and copy-neutral loss of heterozygosity. WNT/β-catenin signaling genes were significantly mutated in all colorectal cancer subtypes, and activated WNT/β-catenin signaling was correlated with the absence of T-cell infiltration. This large-scale genomic analysis of colorectal cancer demonstrates that MSI-high cases frequently undergo an immunoediting process that provides them with genetic events allowing immune escape despite high mutational load and frequent lymphocytic infiltration and, furthermore, that colorectal cancer tumors have genetic and methylation events associated with activated WNT signaling and T-cell exclusion. Significance: This multi-omic analysis of 1,211 colorectal cancer primary tumors reveals that it should be possible to better monitor resistance in the 15% of cases that respond to immune blockade therapy and also to use WNT signaling inhibitors to reverse immune exclusion in the 85% of cases that currently do not. Cancer Discov; 8(6); 730–49. ©2018 AACR. This article is highlighted in the In This Issue feature, p. 663
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures













Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In primary CRC tumor samples, Wnt signaling reduced the frequency of tumor-infiltrating T cells, regardless of mutation load [196].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [196]
In the citing paper
“In addition, APC, as a gene that upregulates WNT signaling, is negatively correlated with the frequency of T cell infiltration [196,197,198].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [196]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400 · cited 1×
“org), using bowtie2 (90) to perform the realignment.”
MethodPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“A main mechanism by which cancers avoid immune attack is by triggering immune checkpoints that are inhibitory pathways crucial for limiting self-attack and minimizing collateral damage in normal tissues (70).”
BackgroundPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · cited 3×
“We were particularly interested in applying this large multi-omic CRC cohort to understand drivers of immune infiltration, since recent advances in immunotherapy have necessitated a deeper consideration of the less frequent MSI-high CRC, which have been shown to respond to immune checkpoint blockade, while the much mo…”
BackgroundMethodThe cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092 · cited 1×
“Precision medicine advances have been fueled by technological advances, such as targeted sequencing, and also by multi-omic sequencing efforts, such as The Cancer Genome Atlas (TCGA)(3), which are powered to provide guidance for targeting molecular observations in the form of estimates of the frequencies of drivers to…”
BackgroundComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 4×
“We were particularly interested in applying this large multi-omic CRC cohort to understand drivers of immune infiltration, since recent advances in immunotherapy have necessitated a deeper consideration of the less frequent MSI-high CRC, which have been shown to respond to immune checkpoint blockade, while the much mo…”
BackgroundMethodInfluentialType, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“We denoted the average log-expression of twelve canonical T-cell-associated genes (CCL2, CCL3, CCL4, CXCL9, CXCL10, CD8A, HLA-DOB, HLA-DMB, HLA-DOA, GZMK, ICOS, and IRF1) as the “T-cell average” for each sample with expression data (45,92,93).”
BackgroundWnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
MacDonald, B. T., Tamai, K., & He, X. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.06.016 · Cited by 5,583 · cited 1×
“We first considered biallelic disruptive mutations in APC, since APC loss results in increased nuclear CTNNB1 thereby driving expression of WNT target genes (68).”
BackgroundMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461 · cited 11×
“A few aspects of the MutsigCV that are gene specific will not be run in this mode, including DNA replication time, chromatin state, and transcription activity.”
BackgroundMethodInfluentialSelf-citationThe consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · cited 6×
“For those samples already analyzed in (35), we used the HLA types provided by (S.S.) and (C.W.); for the remaining samples, we applied seq2HLA to RNAseq data when correctly matepair-labeled paired-end RNAseq data was available, and applied POLYSOLVER to whole-exome data in all other cases.”
MethodInfluentialThe future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · cited 1×
“Antibody therapy can be used to block the CTLA4 or PD-1 (PDCD1) checkpoints, releasing the T-cells to attack the tumor (71,72).”
BackgroundNeoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · cited 1×
“73) and the “CYT” score (the average of GZMA and PRF1 expression, a measure of immune cytolytic activity based on two genes not present in the T-cell average (46); R2 = 0.”
BackgroundSelf-citationBecht, E., Giraldo, N. A., Lacroix, L., Buttard, B., Elarouci, N., Petitprez, F., Selves, J., Laurent-Puig, P., Sautès-Fridman, C., Fridman, W. H., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1070-5 · Cited by 3,685 · cited 2×
“Also, RNAseq-based cell deconvolution of tissue-infiltrating immune and stromal populations using MCP-counter (47) and based on 111 genes, including CD8A and ICOS two genes in the T-cell average measurement, showed that the T-cell average was correlated with all immune cell populations present during immune inflammati…”
MethodInfluentialMutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · cited 2×
“Loss of B2M, long known to be an escape mechanism to cancer immunotherapy strategies (77–79), has been recently shown to confer resistance to anti-PD1 antibody therapy (25,42)(43).”
BackgroundSelf-citationDiscovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Self-citationClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065 · cited 1×
“These T-cells likely recognize neoepitopes created by non-synonymous somatic mutations (73), and result in tumors with higher mutational loads being more likely to respond to immunotherapy (74,75), regardless of tumor type or site of origin (7,8).”
BackgroundSelf-citationMelanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830 · cited 5×
“We denoted the average log-expression of twelve canonical T-cell-associated genes (CCL2, CCL3, CCL4, CXCL9, CXCL10, CD8A, HLA-DOB, HLA-DMB, HLA-DOA, GZMK, ICOS, and IRF1) as the “T-cell average” for each sample with expression data (45,92,93).”
BackgroundMethodInfluentialMechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · cited 1×
“Despite major advances in technologies to monitor complex molecular profiles of cancer, translating molecular observations into treatment decisions remains challenging in routine patient care due to cancer heterogeneity and the rapidly expanding repertoire of treatment options, including immunotherapy (1,2).”
BackgroundThe mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517 · cited 3×
“We used the published and validated methodology in (83) checking to ensure consistency with the TCGA somatic mutation calls available in (4).”
MethodInfluentialSelf-citationCircular binary segmentation for the analysis of array-based DNA copy number data
Olshen, A. B., Venkatraman, E. S., Lucito, R., & Wigler, M. (2004) · Biostatistics · doi:10.1093/biostatistics/kxh008 · Cited by 2,325 · cited 1×
“We segmented the B-allele deficits for each of the samples using the Circular Binary Segmentation Algorithm (91).”
MethodAbsolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,053 · cited 3×
“We used this approach because copy number based approaches, like ABSOLUTE (82), are not effective on samples with few copy number alterations, like MSI-high cases.”
MethodSelf-citationSpranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441 · cited 1×
“Recently, it has been demonstrated that high WNT signaling excludes T cell infiltration in melanoma primary lesions (45), and that T cells failed to control a melanoma tumor with over expression of CTNNB1 (48).”
BackgroundAllele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., Birkbak, N. J., Veeriah, S., Van Loo, P., Herrero, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.001 · Cited by 1,298 · cited 3×
“Using a similar method to the one used here, HLA LOH events were observed recently in lung cancer metastasis with evidence that these cases can iteratively drive immune escape (24).”
BackgroundMethodChemokine expression in melanoma metastases associated with CD8+ T-cell recruitment
Harlin, H., Meng, Y., Peterson, A. C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., & Gajewski, T. F. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2281 · Cited by 1,121 · cited 1×
“We denoted the average log-expression of twelve canonical T-cell-associated genes (CCL2, CCL3, CCL4, CXCL9, CXCL10, CD8A, HLA-DOB, HLA-DMB, HLA-DOA, GZMK, ICOS, and IRF1) as the “T-cell average” for each sample with expression data (45,92,93).”
BackgroundMlecnik, B., Bindea, G., Angell, H. K., Maby, P., Angelova, M., Tougeron, D., Church, S. E., Lafontaine, L., Fischer, M., Fredriksen, T., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.025 · Cited by 1,034
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Dienstmann, R., Vermeulen, L., Guinney, J., Kopetz, S., Tejpar, S., & Tabernero, J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.126 · Cited by 1,021 · cited 2×
“As previously reviewed (16), MSI-high tumors were enriched for hypermethylation (CIMP-high, P < 1×10−15), mutations in BRAF (P < 1×10−15), and RNF43 (P < 1×10−15).”
BackgroundResultResistance to checkpoint blockade therapy through inactivation of antigen presentation
Sade-Feldman, M., Jiao, Y. J., Chen, J. H., Rooney, M. S., Barzily-Rokni, M., Eliane, J.-P., Bjorgaard, S. L., Hammond, M. R., Vitzthum, H., Blackmon, S. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01062-w · Cited by 1,005 · cited 3×
“Loss of B2M, long known to be an escape mechanism to cancer immunotherapy strategies (77–79), has been recently shown to confer resistance to anti-PD1 antibody therapy (25,42)(43).”
BackgroundSelf-citationClassification and characterization of microsatellite instability across 18 cancer types
Hause, R. J., Pritchard, C. C., Shendure, J., & Salipante, S. J. (2016) · Nature Medicine · doi:10.1038/nm.4191 · Cited by 991
Self-citationRecurrent R-spondin fusions in colon cancer
Seshagiri, S., Stawiski, E. W., Durinck, S., Modrusan, Z., Storm, E. E., Conboy, C. B., Chaudhuri, S., Guan, Y., Janakiraman, V., Jaiswal, B. S., et al. (2012) · Nature · doi:10.1038/nature11282 · Cited by 960 · cited 1×
“Supplementary Table 6 shows which genes in Figure 2b were novel with respect to the four previous large-scale whole exome sequencing studies of CRC (1,4,6,21).”
ResultGenomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
Giannakis, M., Mu, X. J., Shukla, S. A., Qian, Z. R., Cohen, O., Nishihara, R., Bahl, S., Cao, Y., Amin-Mansour, A., Yamauchi, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.075 · Cited by 913 · cited 9×
“The significantly mutated genes in MSS were all previously reported in TCGA (4) or in the NHS/HPFS study (6) except for B2M, which is more commonly mutated and significant in MSI-high, occurring less commonly in MSS (Supplementary Table 6).”
BackgroundMethodResultInfluentialSelf-citationAspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
Liao, X., Lochhead, P., Nishihara, R., Morikawa, T., Kuchiba, A., Yamauchi, M., Imamura, Y., Qian, Z. R., Baba, Y., Shima, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207756 · Cited by 843 · cited 3×
“Polymerase chain reaction and pyrosequencing were performed for KRAS (codons 12, 13, 61, and 146) (99), BRAF (codon 600) (96), and PIK3CA (exons 9 and 20) (94).”
BackgroundMethodSelf-citationGettinger, S., Choi, J., Hastings, K., Truini, A., Datar, I., Sowell, R., Wurtz, A., Dong, W., Cai, G., Melnick, M. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0593 · Cited by 787 · cited 2×
“Loss of B2M, long known to be an escape mechanism to cancer immunotherapy strategies (77–79), has been recently shown to confer resistance to anti-PD1 antibody therapy (25,42)(43).”
BackgroundOgino, S., Nosho, K., Kirkner, G. J., Kawasaki, T., Meyerhardt, J. A., Loda, M., Giovannucci, E. L., & Fuchs, C. S. (2009) · Gut · doi:10.1136/gut.2008.155473 · Cited by 777 · cited 2×
“Polymerase chain reaction and pyrosequencing were performed for KRAS (codons 12, 13, 61, and 146) (99), BRAF (codon 600) (96), and PIK3CA (exons 9 and 20) (94).”
MethodSelf-citationFunctionally defined therapeutic targets in diffuse intrinsic pontine glioma
Grasso, C. S., Tang, Y., Truffaux, N., Berlow, N. E., Liu, L., Debily, M.-A., Quist, M. J., Davis, L. E., Huang, E. C., Woo, P. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3855 · Cited by 687
Self-citationComprehensive analysis of cancer-associated somatic mutations in class I HLA genes
Shukla, S. A., Rooney, M. S., Rajasagi, M., Tiao, G., Dixon, P. M., Lawrence, M. S., Stevens, J., Lane, W. J., Dellagatta, J. L., Steelman, S., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3344 · Cited by 675 · cited 13×
“We further examined the correlation between nuclear CTNNB1 and CD3+ cells (pan T-cells), CD8+ cells (cytotoxic T-cells), CD45RO+ cells (antigen-experienced memory T-cells), and FOXP3+ cells (regulatory T-cells, which suppress cytotoxic T-cells).”
InfluentialSelf-citationPersonalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study
Roychowdhury, S., Iyer, M. K., Robinson, D. R., Lonigro, R. J., Wu, Y.-M., Cao, X., Kalyana-Sundaram, S., Sam, L., Balbin, O. A., Quist, M. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003161 · Cited by 628
Self-citationGenome-scale analysis of aberrant DNA methylation in colorectal cancer
Hinoue, T., Weisenberger, D. J., Lange, C. P. E., Shen, H., Byun, H.-M., Van Den Berg, D., Malik, S., Pan, F., Noushmehr, H., van Dijk, C. M., et al. (2012) · Genome Research · doi:10.1101/gr.117523.110 · Cited by 601 · cited 1×
“CpG Island Methylator Phenotype (CIMP) status was called using an array based methylation method (14).”
MethodRestifo, N. P., Marincola, F. M., Kawakami, Y., Taubenberger, J., Yannelli, J. R., & Rosenberg, S. A. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.2.100 · Cited by 533
Nosho, K., Baba, Y., Tanaka, N., Shima, K., Hayashi, M., Meyerhardt, J. A., Giovannucci, E., Dranoff, G., Fuchs, C. S., & Ogino, S. (2010) · The Journal of Pathology · doi:10.1002/path.2774 · Cited by 502 · cited 2×
“We performed immunohistochemistry for CD3, CD8, CD45RO, and FOXP3 as previously described (67).”
MethodSelf-citationRNF43 is frequently mutated in colorectal and endometrial cancers
Giannakis, M., Hodis, E., Jasmine Mu, X., Yamauchi, M., Rosenbluh, J., Cibulskis, K., Saksena, G., Lawrence, M. S., Qian, Z. R., Nishihara, R., et al. (2014) · Nature Genetics · doi:10.1038/ng.3127 · Cited by 470 · cited 2×
“After whole exome sequencing on DNA from tumor and normal FFPE tissue pairs underwent an assay validation using 185 CRC cases in the NHS and HPFS cohorts (64), we conducted whole exome sequencing in additional cases with available ample tissue materials.”
MethodSelf-citationJiménez-Sánchez, A., Memon, D., Pourpe, S., Veeraraghavan, H., Li, Y., Vargas, H. A., Gill, M. B., Park, K. J., Zivanovic, O., Konner, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.025 · Cited by 458 · cited 1×
“Further evidence has demonstrated a role of WNT signaling in shaping immunoresponse in ovarian (49) and prostate cancer (50).”
BackgroundNLR family member NLRC5 is a transcriptional regulator of MHC class I genes
Meissner, T. B., Li, A., Biswas, A., Lee, K.-H., Liu, Y.-J., Bayir, E., Iliopoulos, D., van den Elsen, P. J., & Kobayashi, K. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008684107 · Cited by 447
Challa-Malladi, M., Lieu, Y. K., Califano, O., Holmes, A. B., Bhagat, G., Murty, V. V., Dominguez-Sola, D., Pasqualucci, L., & Dalla-Favera, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.006 · Cited by 439 · cited 1×
“Four additional significantly mutated immune-related genes had been previously described as being expressed in cancer cells: CD58, a tumor surface protein involved in the activation of NK cells through interaction with CD2 (29) that is concurrently lost with B2M in some cancers (30); CASP8, a tumor-expressed gene invo…”
BackgroundOgino, S., Nosho, K., Irahara, N., Meyerhardt, J. A., Baba, Y., Shima, K., Glickman, J. N., Ferrone, C. R., Mino-Kenudson, M., Tanaka, N., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1438 · Cited by 418 · cited 4×
“distinct immune infiltrates in CRC through histopathologic examination of four lymphocytic reaction patterns from: tumor infiltrating lymphocytes, intratumoral periglandular reaction, peritumoral lymphocytic reaction, and Crohn’s-like lymphoid reaction (66) (see Methods), as well as four T-cell functional subsets (CD3…”
BackgroundMethodInfluentialSelf-citationMicrosatellite Instability Detection by Next Generation Sequencing
Salipante, S. J., Scroggins, S. M., Hampel, H. L., Turner, E. H., & Pritchard, C. C. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.223677 · Cited by 399 · cited 1×
“MSI-high status on the remaining samples for which we did not have coverage on these microsatellite markers we relied on a benchmarked bioinformatics approach called mSINGS (11,12), which considers whether there is an increased insertion and deletion (indel) rate at microsatellite tracts throughout the exome (Suppleme…”
MethodSelf-citationSpranger, S., Luke, J. J., Bao, R., Zha, Y., Hernandez, K. M., Li, Y., Gajewski, A. P., Andrade, J., & Gajewski, T. F. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609376113 · Cited by 399 · cited 2×
“To identify T-cell inflammation signature genes that are correlated with T-cell average we followed the method in (56).”
BackgroundMethodNLRC5: a key regulator of MHC class I-dependent immune responses
Kobayashi, K. S., & van den Elsen, P. J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3339 · Cited by 384
MHC-I Genotype Restricts the Oncogenic Mutational Landscape
Marty, R., Kaabinejadian, S., Rossell, D., Slifker, M. J., van de Haar, J., Engin, H. B., de Prisco, N., Ideker, T., Hildebrand, W. H., Font-Burgada, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.050 · Cited by 352
Identification of Genetic Susceptibility Loci for Colorectal Tumors in a Genome-Wide Meta-analysis
Peters, U., Jiao, S., Schumacher, F. R., Hutter, C. M., Aragaki, A. K., Baron, J. A., Berndt, S. I., Bézieau, S., Brenner, H., Butterbach, K., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.12.020 · Cited by 321 · cited 1×
“The National Cancer Institute Genetics and Epidemiology of Colorectal Cancer Consortium (NCI-GECCO) effort, which relies on the TCGA CRC data as a basis for integration of epidemiology data and GWAS data from 40,000 participants to make recommendations regarding CRC prevention (5), pursued the systematic completion of…”
MethodSelf-citationNosho, K., Irahara, N., Shima, K., Kure, S., Kirkner, G. J., Schernhammer, E. S., Hazra, A., Hunter, D. J., Quackenbush, J., Spiegelman, D., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003698 · Cited by 311 · cited 2×
“CIMP-high was defined as methylation in ≥ 6 of eight promoters (97).”
BackgroundSelf-citationD'Urso, C. M., Wang, Z. G., Cao, Y., Tatake, R., Zeff, R. A., & Ferrone, S. (1991) · Journal of Clinical Investigation · doi:10.1172/jci114984 · Cited by 309
Philip, N. H., Dillon, C. P., Snyder, A. G., Fitzgerald, P., Wynosky-Dolfi, M. A., Zwack, E. E., Hu, B., Fitzgerald, L., Mauldin, E. A., Copenhaver, A. M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1403252111 · Cited by 280 · cited 1×
“Four additional significantly mutated immune-related genes had been previously described as being expressed in cancer cells: CD58, a tumor surface protein involved in the activation of NK cells through interaction with CD2 (29) that is concurrently lost with B2M in some cancers (30); CASP8, a tumor-expressed gene invo…”
BackgroundNLRC5/MHC class I transactivator is a target for immune evasion in cancer
Yoshihama, S., Roszik, J., Downs, I., Meissner, T. B., Vijayan, S., Chapuy, B., Sidiq, T., Shipp, M. A., Lizee, G. A., & Kobayashi, K. S. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1602069113 · Cited by 276 · cited 1×
“suggested to be a possible target for immune evasion (41), the size of the gene (1,866 AAs) makes it difficult to identify as significantly mutated by MutSigCV.”
BackgroundHLA typing from RNA-Seq sequence reads
Boegel, S., Löwer, M., Schäfer, M., Bukur, T., de Graaf, J., Boisguérin, V., Türeci, Ö., Diken, M., Castle, J. C., & Sahin, U. (2012) · Genome Medicine · doi:10.1186/gm403 · Cited by 270
Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer
Pritchard, C. C., Morrissey, C., Kumar, A., Zhang, X., Smith, C., Coleman, I., Salipante, S. J., Milbank, J., Yu, M., Grady, W. M., et al. (2014) · Nature Communications · doi:10.1038/ncomms5988 · Cited by 269 · cited 1×
“MSI-high status on the remaining samples for which we did not have coverage on these microsatellite markers we relied on a benchmarked bioinformatics approach called mSINGS (11,12), which considers whether there is an increased insertion and deletion (indel) rate at microsatellite tracts throughout the exome (Suppleme…”
MethodSelf-citationReleasing the Brakes on Cancer Immunotherapy
Ribas, A. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1510079 · Cited by 252 · cited 1×
“Antibody therapy can be used to block the CTLA4 or PD-1 (PDCD1) checkpoints, releasing the T-cells to attack the tumor (71,72).”
BackgroundSelf-citationHSPG Modification by the Secreted Enzyme Notum Shapes the Wingless Morphogen Gradient
Giráldez, A. J., Copley, R. R., & Cohen, S. M. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00180-6 · Cited by 245
Cancer Neoantigens and Applications for Immunotherapy
Desrichard, A., Snyder, A., & Chan, T. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3175 · Cited by 217 · cited 1×
“For example, HLA Class II antigen presenting genes were expressed and not significantly mutated in MSI-high tumors, providing evidence that there is a population for which HLA Class II-based therapies, currently being pursued (80), might prove effective.”
BackgroundHerbst, A., Jurinovic, V., Krebs, S., Thieme, S. E., Blum, H., Göke, B., & Kolligs, F. T. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-74 · Cited by 212
Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer
Heyn, H., Vidal, E., Ferreira, H. J., Vizoso, M., Sayols, S., Gomez, A., Moran, S., Boque-Sastre, R., Guil, S., Martinez-Cardus, A., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-0879-2 · Cited by 208 · cited 1×
“Recent work showed that key WNT signaling genes, including AXIN2, are controlled by super-enhancers, which are continuous genomic regions that drive up gene expression when hypomethylated in cancer (69).”
BackgroundSong, G., Liu, B., Li, Z., Wu, H., Wang, P., Zhao, K., Jiang, G., Zhang, L., & Gao, C. (2016) · Nature Immunology · doi:10.1038/ni.3588 · Cited by 199 · cited 1×
“Four additional significantly mutated immune-related genes had been previously described as being expressed in cancer cells: CD58, a tumor surface protein involved in the activation of NK cells through interaction with CD2 (29) that is concurrently lost with B2M in some cancers (30); CASP8, a tumor-expressed gene invo…”
BackgroundGenetic evolution of T-cell resistance in the course of melanoma progression
Sucker, A., Zhao, F., Real, B., Heeke, C., Bielefeld, N., Maβen, S., Horn, S., Moll, I., Maltaner, R., Horn, P. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0567 · Cited by 171
Hao, H.-X., Jiang, X., & Cong, F. (2016) · Cancers · doi:10.3390/cancers8060054 · Cited by 171
Fu, X., Jeselsohn, R., Pereira, R., Hollingsworth, E. F., Creighton, C. J., Li, F., Shea, M., Nardone, A., De Angelis, C., Heiser, L. M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612835113 · Cited by 169
Self-citationImamura, Y., Lochhead, P., Yamauchi, M., Kuchiba, A., Qian, Z. R., Liao, X., Nishihara, R., Jung, S., Wu, K., Nosho, K., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-135 · Cited by 151
Self-citationHypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine
Nebot-Bral, L., Brandão, D., Verlingue, L., Rouleau, É., Caron, O., Despras, E., Dakdouki, Y. E., Champiat, S., Aoufouchi, S., Leary, A. F., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.026 · Cited by 151 · cited 1×
“An additional rare hypermutation subtype exists in CRC that could be potentially targetable by immune checkpoint inhibitors based on having an unusually high mutation load (13): POLE mutated cases that have mutations in the exonuclease domain of the catalytic subunit of the polymerase epsilon, and which have an outlie…”
BackgroundIrahara, N., Nosho, K., Baba, Y., Shima, K., Lindeman, N. I., Hazra, A., Schernhammer, E. S., Hunter, D. J., Fuchs, C. S., & Ogino, S. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.090106 · Cited by 150 · cited 1×
“U sing bisulfite-treated DNA, methylation status of eight CpG island methylator phenotype (CIMP)-specific promoters (CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1) and long interspersed nucleotide element-1 (LINE-1) was analyzed (97,98).”
Self-citationBeyond β-catenin: prospects for a larger catenin network in the nucleus
McCrea, P. D., & Gottardi, C. J. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.3 · Cited by 142 · cited 1×
“Specifically, we tested 1,150 CRC formalin-fixed paraffin-embedded cases, procured from the NHS/ HPFS cohorts, for nuclear CTNNB1 as a marker of activation of the WNT-signaling pathway (65).”
MethodNLRC5 Cooperates with the RFX Transcription Factor Complex To Induce MHC Class I Gene Expression
Meissner, T. B., Liu, Y.-J., Lee, K.-H., Li, A., Biswas, A., van Eggermond, M. C. J. A., van den Elsen, P. J., & Kobayashi, K. S. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103160 · Cited by 131
Analysis of somatic microsatellite indels identifies driver events in human tumors
Maruvka, Y. E., Mouw, K. W., Karlic, R., Parasuraman, P., Kamburov, A., Polak, P., Haradhvala, N. J., Hess, J. M., Rheinbay, E., Brody, Y., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3966 · Cited by 128 · cited 2×
“A recent study (23) presented a method to use microsatellite indels, which occur at a high rate in MSI-high, to identify cancer drivers.”
MethodRNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis
Bond, C. E., McKeone, D. M., Kalimutho, M., Bettington, M. L., Pearson, S.-A., Dumenil, T. D., Wockner, L. F., Burge, M., Leggett, B. A., & Whitehall, V. L. J. (2016) · Oncotarget · doi:10.18632/oncotarget.12130 · Cited by 108 · cited 5×
“Hao HX, Jiang X, Cong F. Control of Wnt Receptor Turnover by R-spondin-ZNRF3/RNF43 Signaling Module and Its Dysregulation in Cancer.”
BackgroundInfluentialNLRC5 Exclusively Transactivates MHC Class I and Related Genes through a Distinctive SXY Module
Ludigs, K., Seguín-Estévez, Q., Lemeille, S., Ferrero, I., Rota, G., Chelbi, S. T., Mattmann, C., MacDonald, H. R., Reith, W., & Guarda, G. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005088 · Cited by 107 · cited 1×
“It regulates HLA Class I gene expression (40) and has been shown to activate WNT signaling in hepatocellular carcinoma (76), suggesting that master regulators connecting tumor biology and immune response can still be discovered.”
BackgroundElf3 drives β-catenin transactivation and associates with poor prognosis in colorectal cancer
Wang, J.-L., Zf, C., Chen, H.-M., Wang, M.-Y., Kong, X., Wang, Y., Sun, T.-T., Hong, J., Zou, W., Xu, J., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.206 · Cited by 99
Immunotherapy for colorectal cancer: where are we heading?
Basile, D., Garattini, S. K., Bonotto, M., Ongaro, E., Casagrande, M., Cattaneo, M., Fanotto, V., De Carlo, E., Loupakis, F., Urbano, F., et al. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1315405 · Cited by 99 · cited 1×
“On the other hand, it has been postulated that a lower mutational load and poorly characterized effector T cell exclusion processes underlie immunotherapy resistance in MSS CRC (10).”
BackgroundTakahashi, M., Fujita, M., Furukawa, Y., Hamamoto, R., Shimokawa, T., Miwa, N., Ogawa, M., & Nakamura, Y. (2002) · PubMed · Cited by 87
Vogel, K., Bell, L. S., Galloway, A., Ahlfors, H., & Turner, M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600854 · Cited by 84
Liu, X., Zhang, P., Bao, Y., Han, Y., Wang, Y., Zhang, Q., Zhan, Z., Meng, J., Li, Y., Li, N., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301257110 · Cited by 82
Peng, Y., He, Y., Chen, C., Xu, T., Li, L., Ni, M.-M., Meng, X., Huang, C., & Li, J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.006 · Cited by 82
Kawasaki, T., Nosho, K., Ohnishi, M., Suemoto, Y., Kirkner, G. J., Dehari, R., Meyerhardt, J. A., Fuchs, C. S., & Ogino, S. (2007) · Neoplasia · doi:10.1593/neo.07334 · Cited by 80
Self-citationRölle, A., Halenius, A., Ewen, E., Cerwenka, A., Hengel, H., & Momburg, F. (2016) · European Journal of Immunology · doi:10.1002/eji.201646492 · Cited by 73 · cited 2×
“Four additional significantly mutated immune-related genes had been previously described as being expressed in cancer cells: CD58, a tumor surface protein involved in the activation of NK cells through interaction with CD2 (29) that is concurrently lost with B2M in some cancers (30); CASP8, a tumor-expressed gene invo…”
BackgroundMichel, S., Linnebacher, M., Alcaniz, J., Voss, M., Wagner, R., Dippold, W., Becker, C., von Knebel Doeberitz, M., Ferrone, S., & Kloor, M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25106 · Cited by 65 · cited 4×
“01 by a one-sided Fisher’s exact test) consistent with the role of these genes in regulating HLA Class I expression and the role of RFX5 mutations in decreasing HLA Class II expression in MSI-high CRC (44).”
ResultInfluentialJiang, Y., Turinsky, A. L., & Brudno, M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv677 · Cited by 61 · cited 1×
“Calling indels continues to present challenges due to insufficient coverage, alignment quality, the presence of repeats, short interspersed elements and homopolymer/dimers, microsatellite instability, that result in false negatives (88).”
BackgroundSerrated and Non-Serrated Precursor Lesions of Colorectal Cancer
Langner, C. (2014) · Digestive Diseases · doi:10.1159/000366032 · Cited by 57 · cited 1×
“These differences between MSS and MSI-high tumors reflect differences in precursor lesion and etiology (17) that may contribute to responses to immune checkpoint blockade therapy.”
BackgroundCD58, a novel surface marker, promotes self-renewal of tumor-initiating cells in colorectal cancer
Xu, S., Wen, Z., Jiang, Q., Zhu, L., Feng, S., Zhao, Y., Wu, J., Dong, Q., Mao, J., & Zhu, Y. (2014) · Oncogene · doi:10.1038/onc.2014.95 · Cited by 57 · cited 5×
“Four additional significantly mutated immune-related genes had been previously described as being expressed in cancer cells: CD58, a tumor surface protein involved in the activation of NK cells through interaction with CD2 (29) that is concurrently lost with B2M in some cancers (30); CASP8, a tumor-expressed gene invo…”
BackgroundInfluentialImpaired B Cell Development in the Absence of Krüppel-like Factor 3
Vu, T. T., Gatto, D., Turner, V. M., Funnell, A. P. W., Mak, K. S., Norton, L. J., Kaplan, W. H., Cowley, M. J., Agenès, F., Kirberg, J., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101450 · Cited by 53 · cited 1×
“Of these 15 genes, three had known roles in modulating diverse functions in hematopoietic lineage cells and effects beyond antigen presentation but no previously described roles in cancer cells: XYLT2, a gene necessary for dendritic cell traffic and T cell response in the lymph nodes, because of its role in the biosyn…”
BackgroundPredicting tumor purity from methylation microarray data
Zhang, N., Wu, H., Zhang, W., Wang, J., Wu, H., & Zheng, X. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv370 · Cited by 51 · cited 5×
“Tumor purity assessment using methylation data To assess tumor purity, we used DNA methylation levels from a specific set of CpG probes that are differentially methylated between cancer and normal cells, as described in (81) and published as InfiniumPurify.”
MethodInfluentialDirect Transcriptional Consequences of Somatic Mutation in Breast Cancer
Shlien, A., Raine, K. M., Fuligni, F., Arnold, R. R., Nik‐Zainal, S., Dronov, S., Mamanova, L., Rosic, A., Ju, Y. S., Cooke, S. L., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.028 · Cited by 47 · cited 1×
“This data shows that missense mutations are typically expressed, while disruptive mutations result in reduced expression of the variant due to nonsense mediated decay, consistent with (87) (Supplementary Figure 12 and Supplementary Table 2).”
ResultEts2 Regulates Colonic Stem Cells and Sensitivity to Tumorigenesis
Múnera, J. O., Ceceña, G., Jedlicka, P., Wankell, M., & Oshima, R. G. (2011) · Stem Cells · doi:10.1002/stem.599 · Cited by 34
Hechtman, J. F., Sadowska, J., Huse, J. T., Borsu, L. A., Yaeger, R. D., Shia, J., Vakiani, E., Ladanyi, M., & Arcila, M. E. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0062-t · Cited by 30
Reorganisation of Wnt-response pathways in colorectal tumorigenesis
Caldwell, G. M., Jones, C. E., Soon, Y., Warrack, R., Morton, D. G., & Matthews, G. M. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604327 · Cited by 26
A Novel Functional Screen in Human Cells Identifies MOCA as a Negative Regulator of Wnt Signaling
Caspi, E., & Rosin‐Arbesfeld, R. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-10-1046 · Cited by 21 · cited 1×
“On the other hand, AMER1, TGIF1 (51), ELF3 (52), SMAD4, and SMAD2 are significantly mutated in MSS tumors specifically; and ZNRF3 (53), BCL9L, DOCK3 (54), CD58 (55), AXIN2, and WNT16 are significantly mutated in MSI-high tumors.”
BackgroundYin, X., Johns, S., Kim, D., Mikulski, Z., Salanga, C. L., Handel, T., Macal, M., Zúñiga, E., & Fuster, M. (2014) · Journal of Immunology · doi:10.4049/jimmunol.1301286 · Cited by 19 · cited 1×
“Of these 15 genes, three had known roles in modulating diverse functions in hematopoietic lineage cells and effects beyond antigen presentation but no previously described roles in cancer cells: XYLT2, a gene necessary for dendritic cell traffic and T cell response in the lymph nodes, because of its role in the biosyn…”
BackgroundDecreased expression of IDH1-R132H correlates with poor survival in gastrointestinal cancer
Li, J., Huang, J., Huang, F., Jin, Q., Zhu, H., Wang, X., & Chen, M. (2016) · Oncotarget · doi:10.18632/oncotarget.12039 · Cited by 18 · cited 2×
“Li J, Huang J, Huang F, Jin Q, Zhu H, Wang X, et al. Decreased expression of IDH1-R132H correlates with poor survival in gastrointestinal cancer.”
BackgroundTGIF function in oncogenic Wnt signaling
Razzaque, M. S., & Atfi, A. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.10.003 · Cited by 15 · cited 1×
“On the other hand, AMER1, TGIF1 (51), ELF3 (52), SMAD4, and SMAD2 are significantly mutated in MSS tumors specifically; and ZNRF3 (53), BCL9L, DOCK3 (54), CD58 (55), AXIN2, and WNT16 are significantly mutated in MSI-high tumors.”
BackgroundKubo, T., Hirohashi, Y., Matsuo, K., Sonoda, T., Sakamoto, H., Furumura, K., Tsukahara, T., Kanaseki, T., Nakatsugawa, M., Hirano, H., et al. (2017) · Anticancer Research · doi:10.21873/anticanres.11446 · Cited by 14
Assessing the clinical utility of Wnt pathway markers in colorectal cancer.
Veloudis, G., Παππάς, Α., Gourgiotis, S., Falidas, E., Dimitriou, N., Karavokiros, I., Aggelou, A., Komborozos, Petraki, C. D., Menounos, P. G., et al. (2017) · PubMed · Cited by 10
Prostate cancers that ‘Wnt’ respond to abiraterone
Linch, M. D., & Attard, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx785 · Cited by 3 · cited 1×
“Further evidence has demonstrated a role of WNT signaling in shaping immunoresponse in ovarian (49) and prostate cancer (50).”
Background
Cited by
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Cytotoxic CD8+ T cells in cancer and cancer immunotherapy
Raskov, H., Orhan, A., Christensen, J. P., & Gögenur, I. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01048-4 · Cited by 1,687
Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A., & Ribas, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,486
Self-citationConsensus guidelines for the definition, detection and interpretation of immunogenic cell death
Galluzzi, L., Vitale, I., Warren, S., Adjemian, S., Agostinis, P., Martinez, A. B., Chan, T. A., Coukos, G., Demaria, S., Deutsch, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000337 · Cited by 1,119
“125 126 Of note, while the majority of ICD inducers are believed to have little impact on antigenicity and to operate by driving the correct spatiotemporal emission of DAMPs in the context of cell death (see Sources of ICD adjuvanticity ), at least some ICD-triggering regimens may also boost…”
Turning cold tumors into hot tumors by improving T-cell infiltration
Liu, Y.-T., & Sun, Z.-J. (2021) · Theranostics · doi:10.7150/thno.58390 · Cited by 827
Metadata
- Authors
- Grasso, C. S., Giannakis, M., Wells, D. K., Hamada, T., Mu, X. J., Quist, M., Nowak, J. A., Nishihara, R., Qian, Z. R., Inamura, K., Morikawa, T., Nosho, K., Abril-Rodriguez, G., Connolly, C., Escuin-Ordinas, H., Geybels, M. S., Grady, W. M., Hsu, L., Hu-Lieskovan, S., Huyghe, J. R., Kim, Y. J., Krystofinski, P., Leiserson, M. D. M., Montoya, D. J., Nadel, B. B., Pellegrini, M., Pritchard, C. C., Puig-Saus, C., Quist, E. H., Raphael, B. J., Salipante, S. J., Shin, D. S., Shinbrot, E., Shirts, B., Shukla, S., Stanford, J. L., Sun, W., Tsoi, J., Upfill-Brown, A., Wheeler, D. A., Wu, C. J., Yu, M., Zaidi, S. H., Zaretsky, J. M., Gabriel, S. B., Lander, E. S., Garraway, L. A., Hudson, T. J., Fuchs, C. S., Ribas, A., Ogino, S., & Peters, U.
- Affiliations
- University of California, Los Angeles (US)
- Broad Institute (US)
- Parker Institute for Cancer Immunotherapy (US)
- Dana-Farber Cancer Institute (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- 1Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
- Fred Hutch Cancer Center (US)
- University of Washington (US)
- Brown University (US)
- 13Department of Computer Science and Center for Computational Molecular Biology, Brown University, Providence, Rhode Island.
- Baylor College of Medicine (US)
- Ontario Institute for Cancer Research (CA)
- Corresponding author
- Grasso, Catherine S.
- ORCID
- Grasso, Catherine S.
- Giannakis, Marios
- Wells, Daniel K.
- Hamada, Tsuyoshi
- Mu, Xinmeng Jasmine
- Nowak, Jonathan A.
- Nishihara, Reiko
- Qian, Zhi Rong
- Inamura, Kentaro
- Morikawa, Teppei
- Connolly, Charles
- Escuin-Ordinas, Helena
- Grady, William M.
- Hsu, Li
- Huyghe, Jeroen R.
- Kim, Yeon Joo
- Krystofinski, Paige
- Leiserson, Mark D.M.
- Montoya, Dennis J.
- Nadel, Brian B.
- Pellegrini, Matteo
- Pritchard, Colin C.
- Puig-Saus, Cristina
- Salipante, Stephen J.
- Shin, Daniel Sanghoon
- Shinbrot, Eve
- Shirts, Brian
- Shukla, Sachet
- Stanford, Janet L.
- Sun, Wei
- Tsoi, Jennifer
- Upfill-Brown, Alexander
- Wheeler, David A.
- Wu, Catherine J.
- Yu, Ming
- Zaidi, Syed H.
- Zaretsky, Jesse M.
- Gabriel, Stacey B.
- Lander, Eric S.
- Garraway, Levi A.
- Hudson, Thomas J.
- Fuchs, Charles S.
- Ribas, Antoni
- Ogino, Shuji
- Peters, Ulrike
- Venue
- Cancer Discovery
- Published
- 2018-05-31
- Volume
- 8
- Issue
- 6
- Pages
- 730-749
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5984687
- OpenAlex
- W2793126529
- Cited by
- 535
- References
- 103
- Citations by year
- 2026: 47 · 2025: 42 · 2024: 49 · 2023: 73 · 2022: 83 · 2021: 80 · 2020: 76 · 2019: 58 · 2018: 25
- FWCI
- 45.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Cancer Discovery (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- HHS | National Institutes of Health (NIH) (U01 CA137088, K07 CA190673, 1R01CA194663-01, R35 CA197663, P01 CA168585, KL2 TR001100, U54 HG003067, 4T32CA009120-40, P01 CA87969, UM1 CA186107, P01 CA55075, UM1 CA167552, P50 CA127003, R35 CA197735, R01 CA151993)
- American Association for Cancer Research (AACR) (SU2C-AACR-DT22-17)
- HHS | NIH | National Cancer Institute (NCI) (5T32LM012424-03)
- HHS | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (3P50AR063020-03S1)
- Dana-Farber/Harvard Cancer Center (DF/HCC) (Nodal Award)
- American Society of Clinical Oncology (ASCO) (Career Development Award)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- colorectal cancer, immune evasion, microsatellite instability-high, Wnt/β-catenin signaling, T-cell exclusion, immunoediting, antigen presentation, beta2-microglobulin, HLA, copy-neutral loss of heterozygosity, copy number alterations, DNA methylation, immune checkpoint inhibitor resistance, tumor mutational burden, T cell infiltration
- MeSH terms
- beta 2-Microglobulin, HLA Antigens, Humans, Colorectal Neoplasms, Germ-Line Mutation, Tumor Escape, DNA Methylation, Loss of Heterozygosity, Microsatellite Instability, DNA Copy Number Variations, Wnt Signaling Pathway
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.